EFFECT OF ANTICANCER DRUGS ON THE RELEASE OF TUMOR NECROSIS FACTOR INVITRO

被引:7
作者
HASAN, SI
AHMED, K
TURK, JL
机构
[1] Department of Pathology, Royal College of Surgeons of England, London, WC2A 3PN
关键词
D O I
10.1007/BF01786886
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The anticancer drugs Adriamycin, bleomycin, vincristine, 4-hydroperoxycyclophosphamide, FK156 and FK565 and the immunosuppressive drug cyclosporin-A were tested for their effect on lipopolysaccharide-induced tumour necrosis factor-α (TNF) release from rat peritoneal exudate cells in vitro. FK565 resulted in a marked enhancement of TNF release when added to cultures at doses of 1 μg/ml and 10 μg/ml. However, FK156, Adriamycin, bleomycin, 4-hydroperoxycyclophosphamide, vincristine and cyclosporin A did not affect the release of TNF under the same conditions. Puromycin inhibited the release of TNF in the same system at non-cytotoxic doses of 1 μg/ml and 10 μg/ml. © 1990 Springer-Verlag.
引用
收藏
页码:363 / 366
页数:4
相关论文
共 17 条
[1]   INHIBITION OF RELEASE OF INTERLEUKIN-2 BY VINCRISTINE AND VINBLASTINE [J].
AHMED, K ;
HAMIED, TAA ;
TURK, JL .
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 1987, 9 (04) :391-407
[2]  
AHMED K, 1989, CANCER IMMUNOL IMMUN, V28, P87
[3]  
BATE CAW, 1989, IMMUNOLOGY, V66, P600
[4]   PURIFICATION OF CACHECTIN, A LIPOPROTEIN-LIPASE SUPPRESSING HORMONE SECRETED BY ENDOTOXIN-INDUCED RAW 264.7 CELLS [J].
BEUTLER, B ;
MAHONEY, J ;
LETRANG, N ;
PEKALA, P ;
CERAMI, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1985, 161 (05) :984-995
[5]   CYCLOSPORIN-A MEDIATES IMMUNOSUPPRESSION OF PRIMARY CYTO-TOXIC T-CELL RESPONSES BY IMPAIRING THE RELEASE OF INTERLEUKIN-1 AND INTERLEUKIN-2 [J].
BUNJES, D ;
HARDT, C ;
ROLLINGHOFF, M ;
WAGNER, H .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1981, 11 (08) :657-661
[6]  
CURRIE GA, 1985, J EXP MED, V142, P1600
[7]  
DAMMACCO F, 1988, RECENT ADV AUTOIMM 2, P157
[8]   INTERLEUKIN-1 [J].
DINARELLO, CA .
REVIEWS OF INFECTIOUS DISEASES, 1984, 6 (01) :51-95
[9]  
HAMIED TAA, 1987, CANCER IMMUNOL IMMUN, V25, P245
[10]  
HAMIED TAA, 1987, INT J IMMUNOPHARMACO, V9, P35